Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.49 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.49 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | F9 | P00740 | 16/20 | 0.46 |
| ▸ | F10 | P00742 | 8/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709689 | 0.82 | F9 (0.58) | F9F10 | |
| SCHEMBL13709679 | 0.79 | F9 (0.53) | F9F10 | |
| SCHEMBL13709685 | 0.78 | F9 (0.71) | F9F10 | |
| SCHEMBL13709732 | 0.77 | F9 (0.52) | F9F10 | |
| SCHEMBL13709691 | 0.77 | F9 (0.59) | F9F10 | |
| SCHEMBL13709713 | 0.77 | F9 (0.48) | F9F10 | |
| SCHEMBL13709718 | 0.75 | F9 (0.47) | F9F10 | |
| SCHEMBL13709677 | 0.75 | F9 (0.72) | F9F10 | |
| SCHEMBL13709766 | 0.74 | F9 (0.46) | F9F10 | |
| SCHEMBL13709710 | 0.74 | F9 (0.70) | F9F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | F12, F5, F3 | TPSAB1 663/4885TPSD1 830/4885TPSG1 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.